Adocia: Positive Phase 3 Results with Tonghua Dongbao
Adocia announced the completion of the Phase 3 program for BioChaperone® Lispro with its Chinese partner Tonghua Dongbao, showing positive results in patients with type 1 and type 2 diabetes. The biotech company based in Lyon continues to develop its technology platforms in collaboration with two major pharmaceutical companies.
Completion of Phase 3 Program
Tonghua Dongbao has completed the Phase 3 program for BioChaperone® Lispro, an ultra-rapid insulin. In July 2025, positive trial results in patients with type 2 diabetes demonstrated non-inferiority in reducing HbA1c at 26 weeks compared to Humalog®, as well as a significant reduction in glycemic excursion after a test meal. In October 2025, positive results were also announced in patients with type 1 diabetes, showing non-inferiority in reducing HbA1c and a significant reduction in post-meal glycemic excursion. The study included approximately 1,500 individuals with type 1 or type 2 diabetes.
Financial Terms and Milestone Payments
The agreement includes a milestone payment of 20 million U.S. dollars contingent upon market authorization in China, as well as double-digit royalties on sales. A milestone payment of 10 million U.S. dollars was triggered in December 2024 by the administration of the last dose to the last patient with type 2 diabetes, which was received in July 2025 for a net amount of 9 million U.S. dollars after a 10% withholding tax.
Ongoing Development and New Patent
Adocia continues the development of BioChaperone® to stabilize and combine peptides aimed at treating obesity and diabetes, with two feasibility studies currently underway in collaboration with two major pharmaceutical companies. The company has filed a patent for the new AdoXLong™ platform, designed to enable monthly peptide injections, with preliminary positive in vitro and in vivo results obtained with semaglutide.
